

3^{RD} ANNUAL **ACT MEETING** 2024 BIOTECH

PROSPECTUS



Accélérer les Essais Cliniques

Join us October 9-10, 2024 for the 3rd Annual ACT Meeting! in Quebec City, QC

Explore international developments and collaboration opportunities in clinical trials!

Highlights include:

- Exploring strategies to foster a vibrant Canadian biotechnology ecosystem
- Updates on new ACT-funded clinical trial networks
- Announcements of the single national REB winners
- Updates on the work of our ACT committees
- Discussions about regulatory processes in Canada

Don't miss this opportunity for valuable insights and networking, advancing clinical trial excellence both nationally and globally.



ACC Accelerating Clinical Trials ACCélérer les Essais Cliniques

About The ACT Consortium

Our Mission

The Accelerating Clinical Trials (ACT) Canada Consortium was established with CIHR funding and pan-Canadian participants to facilitate, optimize, and accelerate the conduct, implementation, and result translation from highquality, high-impact randomized controlled trials to improve health in Canada and globally.

Since 2023, ACT has established a network of 34 research networks, 11 clinical trial units, and 20 community hospitals, facilitating collaboration across Canada. Additionally, our consortium committees and working groups include patient partners, biotechnology industry leaders, and research ethics review experts. We provide guidance and guidelines on various clinical trials processes, including contracts, regulatory processes, patient engagement, training, and knowledge mobilization to improve the Canadian clinical trials ecosystem.


Accelerating Clinical Trials Accélérer les Essais Cliniques

Our Audience



Readers


Previous annual meeting attendees included researchers, patient partners, and International clinical trial experts.





Accelerating 👾 Clinical Trials Accélérer les Essais Cliniques

A Snapshot of ACT's 3rd Annual Meeting





Anticipated attendees from across Canada



Accelerating Clinical Trials Accélérer les Essais Cliniques

Biotech Opportunity

In preparation for the Third ACT Consortium Meeting, we are seeking Canadian biotechnology companies to collaborate with ACT Canada researchers on randomized controlled trials (RCTs).

Companies will have the opportunity to pitch their innovations to a variety of ACT Members through presentations and/or exhibit tables in conference rooms at our October 9-10, 2024 meeting in Quebec City.

To ensure that these companies are a good fit for this meeting, and the RCT funding opportunity that will be announced in Fall 2024, we are scheduling pre-interviews using <u>this pre-registration form</u>.

For more information, <u>visit our</u> <u>website</u> or reach out to us at <u>ACT.Canada@PHRI.ca</u>.



Accelerating Clinical Trials Accélérer les Essais Cliniques

The Agenda at a Glance

Wednesday October 9th, 2024

- 8:00 am Meeting opening and keynote (WHO Guidance for best practices for clinical trials)
- 9:30 am Canadian Biotechnology presentations
- 10:30 am Break Exhibitor booth walk about
- 11:00 am Third ACT RFA awardees' presentations
- 11:30 am Canadian Biotechnology presentations
- 12:30 pm Grab & Go Lunch Exhibitor booth walk about
- 1:30 pm Insight on conducting large international trials
- 2:00 pm Canadian Biotechnology Presentations
- 3:00 pm Break Exhibitor booth walk about
- 3:30 pm Conducting large international trials in India
- 4:00 pm Single National REB RFA Update
- 4:30 pm Patient engagement committee update
- 5:00 pm Day 1 Closing remarks

Thursday October 10th, 2024

- 8:00 am RFA 4 Winners
- 9:00 am Canadian Biotechnology presentations
- 10:00 am Break Exhibitor booth walk about
- 10:30 am Presentations (discussion on circle of care requirements, clinical trials training partners presentations)
- 12:15 pm Grab & Go Lunch Exhibitor booth walk about
- 1:30 pm Breakout groups to discuss Health Canada inspections
- 4:00 pm Day 2 Closing remarks



Accelerating Clinical Trials Accélérer les Essais Cliniques

Join Us 3rd ACT Annual Meeting

act.canada@phri.ca